
We are developing the future of drug discovery with a platform to discover, develop, and deliver drug candidates for challenging targets. Sign up for our quarterly newsletter to keep up with our…

We are developing the future of drug discovery with a platform to discover, develop, and deliver drug candidates for challenging targets. Sign up for our quarterly newsletter to keep up with our…
Founded / Launch: February 29, 2024
Headquarters: Copenhagen and Lausanne
Technology: AI-enabled nGen platform for orally dosable macrocycles
Total reported funding: €116M (seed + Series A)
Employee count (reported): 45
Drug discovery and development for oral macrocycle therapeutics; replacing injectable biologics.
2024
Biotechnology / Biopharmaceuticals
€26M
Company launch announcement accompanied seed financing
€90M
Series A brought total reported funding to €116M; other participants included Forbion, Novo Holdings, Lilly Ventures, Cormorant, and the Export and Investment Fund of Denmark
“Investors include venture funds and corporate VC (Novo Holdings, Forbion, NEA, Lilly Ventures) and institutional/co-investors (Cormorant, Export and Investment Fund of Denmark)”
| Company |
|---|
Drive the evolution of the industry’s most advanced automated platform for macrocycle drug discovery
This is your chance to lead the chemistry engine of a company that is at the forefront of macrocycle innovation by
About the role
Orbis is now seeking a visionary VP Platform Chemistry to lead, expand, and continuously innovate the automated macrocycle chemistry engine.
This is a role for a scientific and operational leader who thrives at the intersection of automation, chemistry innovation, platform engineering, and cross-functional drug discovery. You will set the strategic direction for the chemistry platform, ensure world-class execution, and drive scientific breakthroughs that unlock the full potential of macrocycles as an oral modality.
As VP Platform Chemistry, you will be the strategic and scientific leader responsible for the design,
development, and scaling of Orbis’ automated macrocycle synthesis platform.
Your responsibilities will include:
Strategic Leadership
Platform Ownership
Team & Cross-Site Leadership
Execution & Delivery
You will report to the EVP Early Discovery & Platform Technologies.
Your Skills and Expertise
You are expected to bring a unique combination of deep scientific expertise, platform thinking, and leadership capability like:
Leadership Attributes
Application
Please apply via the link.
Orbis Medicines collaborates with DEDENROTH on this recruitment.
Please contact Mia Danielsen to express your interest or if you have any questions about the role or the process.
Phone: +45 26178142 / Email: mia.danielsen@orbismedicines.com
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
65,000+
Open Roles
1,500+
New This Week